For Institutions
About
Natera's new clinical data strengthens the investment narrative for its Signatera ctDNA assays, highlighting their role in guiding treatment choices and refining recurrence risk. Despite growing validation, profitability risks remain due to heavy investment and potential reimbursement shifts. Natera projects $3 billion revenue by 2028, with fair value estimates ranging widely. Investors should consider clinical adoption and reimbursement as key catalysts for future performance.
Praxis Precision Medicines (PRAX) has restructured its EMBRAVE3 trial for elsunersen following a Type C meeting with the FDA, leading to a significant stock price increase. Despite a high price-to-book ratio of 19.9x, indicating a premium valuation, a DCF model suggests the stock may be undervalued. The company's recent regulatory success and potential future growth are key factors for investors, though risks remain if trial setbacks occur. The stock's valuation is notably higher than industry norms, reflecting high market expectations.
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) has received a consensus recommendation of 'Moderate Buy' from seventeen ratings firms. The average twelve-month price target is $403.80. Recent ratings include 'strong-buy' from Lifesci Capital, 'buy' from Needham & Company LLC, and 'overweight' from Piper Sandler. Insiders have sold significant shares recently. Hedge funds and institutional investors have adjusted their stakes in the company. The stock opened at $272.92 on Friday, with a market cap of $6.83 billion.
Anzalone Christopher Richard, Chairman of Arrowhead Pharmaceuticals Inc [ARWR], filed a Form 4 with the SEC on December 19, 2025, disclosing the surrender of 85,000 shares at $64.04 each, valued at $5,443,460. The surrender was to pay option exercise costs and/or resulting tax liability. His ending holdings are 3,831,957 shares directly.
Illumina Inc. (ILMN) shares rose 3.27% to $134.78 on Friday, outperforming competitors in a strong trading session. The S&P 500 Index increased by 0.88% and the Dow Jones Industrial Average by 0.38%. This marks the second consecutive day of gains for Illumina, closing 11.94% below its 52-week high. Trading volume was significantly higher than the 50-day average.
